Hemostemix Inc. Share Price

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 14:40:57 07/08/2026 BST			5-day change	1st Jan Change
0.0700 ^CAD	+7.69%		+16.67%	-22.22%

07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT

News in other languages: Hemostemix Inc.

10/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
22/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
09/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	09/02/2020
Christina Wu DFI	Director of Finance/CFO	-	04/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	13/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	25/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	08/02/2020
Loran Swanberg BRD	Director/Board Member	-	07/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	CA$0.0700	+7.69%	1,001
06/08/26	CA$0.0650	0.00%	5,465
05/08/26	CA$0.0650	+8.33%	8,911
31/07/26	CA$0.0600	0.00%	24,384

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Market Cap	13.85M 9.94M 8.59M 8.03M 7.36M 946M 14.07M 94.16M 36.96M 474M 37.31M 36.49M 1.57B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	16.71M 11.99M 10.37M 9.68M 8.88M 1.14B 16.97M 114M 44.59M 572M 45.02M 44.03M 1.89B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	82.86%	Yield 2024 *	-	Yield 2025	-

07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-16	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-20	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT
12-30	Hemostemix Inc. announced that it has received CAD 0.48 million in funding	CI
12-23	Hemostemix Inc Appoints David B. Alper as Member of Scientific Advisory Board, Effective January 2026	CI

07-28	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
07-22	Hemostemix : grants 6,280,000 options	PU
07-22	Hemostemix Grants Stock Options	NE
07-08	Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain	NE
06-26	Hemostemix Closes $360,000 First Tranche of Private Placement	NE

1 week	0.06	0.07
1 month	0.06	0.07
Current year	0.04	0.11
1 year	0.04	0.14
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5.9

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/07/26	Peter Lacey	Option	Chairman	525,000	0.2654%
22/07/26	Loran Swanberg	Option	Director	385,000	0.1946%
22/07/26	Thomas Smeenk	Option	Founder	1,730,000	0.8746%

Hemostemix Inc. Share Price

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news : Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+7.69%
1 week	+16.67%
Current month	+16.67%
1 month	+16.67%
3 months	+16.67%
6 months	-22.22%
Current year	-22.22%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	+7.69%	+16.67%	-12.50%	-53.33%	9.94M
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+70.77%	+110.32%	68.12B
ARGENX SE	+1.25%	+2.44%	+34.27%	+70.43%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.67%	+494.56%	28.63B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+56.20%	+6.03%	23.99B
BIONTECH SE	+2.72%	+3.41%	-16.11%	-7.96%	23.53B
GENMAB A/S	+6.50%	+7.56%	+44.65%	-21.73%	18.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+33.87%	+693.38%	16.44B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+359.77%	15.83B
EXELIXIS, INC.	+3.58%	+1.96%	+43.35%	+163.76%	13.4B
Average	+4.23%	+12.18%	+47.35%	+181.52%	26.36B
Weighted average by Cap.	+4.36%	+13.10%	+50.69%	+168.47%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.88M -1.62M -1.52M -1.39M -179M -2.66M -17.79M -6.98M -89.55M -7.05M -6.9M -296M	-4.71M -3.38M -2.93M -2.73M -2.51M -322M -4.79M -32.05M -12.58M -161M -12.7M -12.42M -533M
Net Debt	4.23M 3.04M 2.63M 2.45M 2.25M 289M 4.3M 28.77M 11.29M 145M 11.4M 11.15M 479M	2.86M 2.05M 1.78M 1.66M 1.52M 195M 2.91M 19.45M 7.64M 97.92M 7.71M 7.54M 324M